Abstracts tagged "B cells"

Abstract Number: 30 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiling Analysis Of Human B-Cell Subsets In Health and Systemic Lupus Erythematosus
Chungwen Wei¹, Edward Ramos², Norm Allaire³, Suzanne Szak³, Susan Kalled³, Ann Ranger³ and Ignacio Sanz¹, ¹Rheumatology, Emory University, Atlanta, GA, ²Biology, Emory University, Atlanta, GA, ³Biogen Idec Inc, Cambridge, MA
Background/Purpose: SLE is an autoimmune disease, which exhibits multiple B cell abnormalities including expanded populations of plasmablasts and DN memory cells as well as a…
Abstract Number: 1874 • 2013 ACR/ARHP Annual Meeting
Genome-Wide Profiling Identifies Significant Differences Between The T-Lymphocyte and B-Lymphocyte Methylomes In Healthy Individuals
John Glossop^1,2, Nicola Nixon², Richard Emes³, Kim Haworth¹, Jonathon Packham², Peter Dawes², Anthony Fryer¹, Derek Mattey^1,2 and William Farrell¹, ¹Institute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, United Kingdom, ²Rheumatology, Haywood Rheumatology Centre, Stoke-on-Trent, United Kingdom, ³School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonnington, United Kingdom
Background/Purpose: Multiple reports now describe changes to the DNA methylome in a variety of autoimmune disorders, such as rheumatoid arthritis. In many cases, these studies…
Abstract Number: 918 • 2013 ACR/ARHP Annual Meeting
Regulatory B Cells Suppress Skin Inflammation in a Murine Model of Psoriasis
Koichi Yanaba¹ and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Psoriasis is a cutaneous disorder characterized by widespread erythematous plaques with adherent scales. Recent studies have revealed that both T helper (Th) 17 and…
Abstract Number: 32 • 2013 ACR/ARHP Annual Meeting
Understanding The Stimulatory Pathways Responsible For Naïve B Cell Activation In Systemic Lupus Erythematosus
Emily Blalock¹, Chris Scharer², Scott Jenks¹, Jeremy Boss² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a recurrent autoimmune disease characterized by multiple B cell abnormalities, including the activation of naïve B cells. However, gaps…
Abstract Number: 1867 • 2013 ACR/ARHP Annual Meeting
Profiling Cytokine Production Of B Cells From SLE Patients Upon TLR9 Stimulation
Julia Sieber¹, Capucine Daridon², Simon Fillatreau³ and Thomas Dörner¹, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ³German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany
Background/Purpose: Beyond their antibody producing function, B cells have been shown to be potent antigen-presenting and cytokine-producing cells. In systemic lupus erythematosus (SLE), B cells…
Abstract Number: 919 • 2013 ACR/ARHP Annual Meeting
B Cell Derived IFN-γ Contributes To The Negative Regulation Of T-Regulatory Cell Differentiation In Arthritis
Susan Olalekan¹, Yanxia Cao² and Alison Finnegan², ¹Immunology, Rush University Medical Center, Chicago, IL, ²Dept of Medicine, Rush University Medical Center, Chicago, IL
Background/Purpose: Depletion of B cells using a monoclonal antibody against CD20 expressed on mature B cells has proven efficacious in patients with rheumatoid arthritis (RA).…
Abstract Number: 33 • 2013 ACR/ARHP Annual Meeting
B Cell Receptor Signaling As A Potential Clinical Parameter In Lupus
Michael Faludi¹, Christian A. Pineau², Evelyne Vinet¹, Ann E. Clarke³, Sasha Bernatsky⁴, Joyce Rauch² and Emil P. Nashi⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²Rheumatology, McGill University Health Center, Montreal, QC, Canada, ³Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁴Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada, ⁵Immunology and Rheumatology, McGill University Health Center, Montreal, QC, Canada
Background/Purpose: B cells are central to SLE. Signaling through the B cell receptor (BCR) controls critical processes at various stages of B cell development. Murine…
Abstract Number: 1776 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis
Rohit Aggarwal¹, Chester V. Oddis², Erich R Wilkerson³, Diane Koontz⁴, Ilinca D. Metes⁵, Ann M. Reed⁶, Dana P. Ascherman⁷ and Marc C. Levesque⁸, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: B cell subset numbers, especially lower memory B (Bmem) cells, predict clinical responsiveness to rituximab in several diseases including pemphigus and rheumatoid arthritis (RA).…
Abstract Number: 920 • 2013 ACR/ARHP Annual Meeting
Fms-Like Tyrosine Kinase 3 Signaling Is Essential For Differentiation Of Antigen Specific Plasma Cells During Experimental Arthritis
Mattias Svensson¹, Kersti Månsson¹, Karin Andersson¹, Mats Bemark², Mikael Brisslert¹ and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Signaling through the tyrosine kinase receptor Flt3 plays an important role in early B-cell development. Mice lacking either Flt3 or its ligand (Flt3L) have…
Abstract Number: 34 • 2013 ACR/ARHP Annual Meeting
Dichotomous Responses Of Human Systemic Lupus Erythematosus B Cell Subsets To B Cell Receptor Stimulation
Franziska Matzkies¹, Anthony DeFranco², Andrew J. Gross³, Maria Dall'era⁴ and Michelle Hermiston⁵, ¹Medicine- Rheumatology, University of California, San Francisco, San Francisco, CA, ²Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Hematology/Oncology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Autoantibody production is a hallmark of Systemic Lupus Erythematosus (SLE), supporting a central role for B cells in disease pathogenesis. Prior studies have demonstrated…
Abstract Number: 1732 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
MC Genovese¹, Gregg J. Silverman², Paul Emery³, Ramesh Gupta⁴, Anne Gill⁵, Wendy J. Komocsar⁵, Melissa Veenhuizen⁵, Li Xie⁵, Pierre-Yves Berclaz⁵ and Chin Lee⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Rheumatology, NYU School of Medicine, New York, NY, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Private Practice, Memphis, TN, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF). These interim analyses evaluated the efficacy and safety of…
Abstract Number: 921 • 2013 ACR/ARHP Annual Meeting
Blocking The Complement Receptor 2 (CR2) Ligand-Receptor Interaction With a Novel Mouse Anti-Mouse CR2 Monoclonal Antibody Decreases Antigen-Specific Humoral Immune Responses and The Evolution Of Collagen-Induced Arthritis
Rosa Rodriguez¹, Liudmila Kulik¹, Joshua Thurman², Jonathan Hannan¹, Steve Tomlinson³ and V. Michael Holers¹, ¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ²Renal Division, University of Colorado School of Medicine, Aurora, CO, ³Microbiology and Immunology, Medical University of South Carolina, Charleston, NC
Background/Purpose: The CR2/CD19 complex on B cells serves as a co-receptor for membrane IgM and amplifies B cell responses through physical associations of the bound…
Abstract Number: 36 • 2013 ACR/ARHP Annual Meeting
IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus
Joan E. Wither¹, Nan-Hua Chang², Timothy Li³, Julie Kim⁴, Carolina Landolt-Marticorena⁵, Paul R. Fortin⁶, Dafna D. Gladman⁷ and Murray B. Urowitz⁸, ¹1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Previous experiments suggest that the B cells of lupus patients are hyper-responsive to B cell receptor engagement resulting in increased tyrosine phosphorylation and Ca2+mobilization. …
Abstract Number: 1742 • 2013 ACR/ARHP Annual Meeting
Effects Of Blisibimod, An Inhibitor Of B Cell Activating Factor, On Serum Immunoglobulins and Infection Risk In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on IgG, IgM and infection risk in patients…
Abstract Number: 924 • 2013 ACR/ARHP Annual Meeting
B Cell Subsets and Dysfunction Of Regulatory B Cells In IgG4-Related Diseases and Primary Sjögren Syndrome: The Similarities and Differences
Wei Lin¹, Lixia Jin², Wen Zhang¹, Hua Chen³, QingJun Wu⁴, Yunyun Fei¹, Yan Zhao¹, Xiaofeng Zeng⁵ and Fengchun Zhang³, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Tsinghua University, Beijing, China, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: IgG4 related disease (IgG4-RD) is a chronic, multisystem-involved autoimmune disease. Abnormally activated and differentiated B cells may play important roles. Regulatory B cells (Breg)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].